Immunovant Executive Compensation (FY26)
IMVT · Executive and director compensation, fiscal 2024 to 2026
The Immunovant brief, $1,500
Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
Both reports for $2,400.
Data as of September 21, 2026Latest filing (8-K): September 3, 2026
8 filings cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
$1,500Get the executive brief
319 figures on this page: 313 cited to the filing that reported them, 6 calculated from figures it prints. See the citations
What changed from fiscal 2025 to fiscal 2026
The figures that moved, and by how much. Analysis of these figures is part of the Velarion platform.
Chief executive of record: Peter Salzmann → Eric Venker
CEO pay ratio: 29:1 → 67:1 (131.0% higher)
Frequently asked questions
Answers drawn from the data on this page.
Who is Immunovant's chief executive and what were they paid?
Eric Venker, Chief Executive Officer, received $20,158,767 in total compensation for fiscal 2026.
What was Immunovant's say-on-pay result?
For fiscal 2026, the say-on-pay proposal drew 95.5% support at the meeting held September 2, 2026.
Which companies are in Immunovant's peer group?
The disclosed peer group includes Apogee Therapeutics, Arcellx, Arrowhead Pharmaceuticals, Biohaven and BridgeBio Pharma, among others.
What is Immunovant's chief executive pay ratio?
The disclosed chief executive pay ratio for fiscal 2026 is 67:1, against median employee compensation of $303,366.
Executive compensation
Every element reported for each named executive officer, by fiscal year.
Fiscal 2024
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
Peter Salzmann Former Chief Executive Officer | ◇ | ◇ | ◇ | ◇ | — | — | ◇ | ◇ |
Jay Stout Chief Technology Officer | ◇ | ◇ | ◇ | ◇ | — | — | ◇ | ◇ |
Eva Renee Barnett Former Chief Financial Officer | ◇ | ◇ | ◇ | ◇ | — | — | ◇ | ◇ |
Fiscal 2025
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
Peter Salzmann Former Chief Executive Officer Departed during or after this year | ◇ | ◇ | ◇ | ◇ | — | — | ◇ | ◇ |
Christopher Van Tuyl Chief Legal Officer and Corporate Secretary | ◇ | ◇ | ◇ | ◇ | — | — | ◇ | ◇ |
Melanie Gloria Chief Operating Officer | ◇ | ◇ | ◇ | ◇ | — | — | ◇ | ◇ |
Michael Geffner Chief Medical Officer | ◇ | ◇ | ◇ | ◇ | — | — | ◇ | ◇ |
Jay Stout Chief Technology Officer | ◇ | ◇ | ◇ | ◇ | — | — | ◇ | ◇ |
Eva Renee Barnett Former Chief Financial Officer Departed during or after this year | ◇ | ◇ | ◇ | ◇ | — | — | ◇ | ◇ |
Fiscal 2026
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
Eric Venker Chief Executive Officer | ◇ | ◇ | — | ◇ | — | — | ◇ | ◇ |
Peter Salzmann Former Chief Executive Officer Departed during or after this year | ◇ | — | ◇ | ◇ | — | — | ◇ | ◇ |
Tiago Girão Chief Financial Officer | ◇ | ◇ | ◇ | ◇ | — | — | ◇ | ◇ |
Michael Geffner Former Chief Medical Officer Departed during or after this year | ◇ | — | ◇ | ◇ | — | — | ◇ | ◇ |
Eva Renee Barnett Former Chief Financial Officer Departed during or after this year | ◇ | — | ◇ | ◇ | — | — | ◇ | ◇ |
Melanie Gloria Chief Operating Officer | ◇ | ◇ | ◇ | ◇ | — | — | ◇ | ◇ |
Jay Stout Chief Technology Officer | ◇ | ◇ | ◇ | ◇ | — | — | ◇ | ◇ |
Christopher Van Tuyl Chief Legal Officer and Corporate Secretary | ◇ | ◇ | ◇ | ◇ | — | — | ◇ | ◇ |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.
Equity awards granted
Individual awards as disclosed: type, date, unit counts at each level, and grant date value.
Fiscal 2026
| Officer | Award | Grant date | Threshold units | Target units | Units granted | Maximum units | Exercise price | Grant date fair value |
|---|---|---|---|---|---|---|---|---|
| Christopher Van Tuyl | RSU | ◇ | — | — | ◇ | — | — | ◇ |
| Christopher Van Tuyl | OPTION | ◇ | — | — | ◇ | — | ◇ | ◇ |
| Eric Venker | OPTION | ◇ | — | — | ◇ | — | ◇ | ◇ |
| Eric Venker | RSU | ◇ | — | — | ◇ | — | — | ◇ |
| Eric Venker | OPTION | ◇ | — | — | ◇ | — | ◇ | ◇ |
| Eva Renee Barnett | OPTION | ◇ | — | — | ◇ | — | — | ◇ |
| Eva Renee Barnett | RSU | ◇ | — | — | ◇ | — | — | ◇ |
| Eva Renee Barnett | OPTION | ◇ | — | — | ◇ | — | ◇ | ◇ |
| Jay Stout | RSU | ◇ | — | — | ◇ | — | — | ◇ |
| Jay Stout | PSU | ◇ | — | ◇ | ◇ | — | — | — |
| Jay Stout | OPTION | ◇ | — | — | ◇ | — | ◇ | ◇ |
| Melanie Gloria | OPTION | ◇ | — | — | ◇ | — | ◇ | ◇ |
| Melanie Gloria | RSU | ◇ | — | — | ◇ | — | — | ◇ |
| Melanie Gloria | PSU | ◇ | — | ◇ | ◇ | — | — | — |
| Michael Geffner | OPTION | ◇ | — | — | ◇ | — | ◇ | ◇ |
| Michael Geffner | RSU | ◇ | — | — | ◇ | — | — | ◇ |
| Michael Geffner | PSU | ◇ | — | ◇ | ◇ | — | — | — |
| Michael Geffner | OPTION | ◇ | — | — | ◇ | — | — | ◇ |
| Michael Geffner | RSU | ◇ | — | — | ◇ | — | — | ◇ |
| Peter Salzmann | OPTION | ◇ | — | — | ◇ | — | ◇ | ◇ |
| Peter Salzmann | RSU | ◇ | — | — | ◇ | — | — | ◇ |
| Peter Salzmann | RSU | ◇ | — | — | ◇ | — | — | ◇ |
| Peter Salzmann | OPTION | ◇ | — | — | ◇ | — | — | ◇ |
| Tiago Girão | OPTION | ◇ | — | — | ◇ | — | ◇ | ◇ |
| Tiago Girão | RSU | ◇ | — | — | ◇ | — | — | ◇ |
| Tiago Girão | RSU | ◇ | — | — | ◇ | — | — | ◇ |
Fiscal 2025 are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. Threshold, target and maximum apply only to performance awards and are never shown for time-based or option awards.
Outstanding awards
Awards still held at fiscal year end.
As disclosed at fiscal 2026 year end
| Officer | Award | Unvested units | Market value of unvested units | Exercise price | Expires |
|---|---|---|---|---|---|
| Jay Stout | Option | ◇ | — | ◇ | 4/17/2033 |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | 4/1/2035 | |
| Option | ◇ | — | ◇ | 4/2/2034 | |
| RSU | ◇ | ◇ | — | — | |
| Peter Salzmann | RSU | ◇ | ◇ | — | — |
| Option | ◇ | — | ◇ | 7/20/2026 | |
| Option | ◇ | — | ◇ | 7/20/2026 | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | 7/20/2026 | |
| RSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | 7/20/2026 | |
| Michael Geffner | Option | ◇ | — | ◇ | 1/30/2027 |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | 1/30/2027 | |
| RSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | 1/30/2027 | |
| RSU | ◇ | ◇ | — | — | |
| Christopher Van Tuyl | Option | ◇ | — | ◇ | 12/16/2034 |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | 4/1/2035 | |
| Tiago Girão | RSU | ◇ | ◇ | — | — |
| Option | ◇ | — | ◇ | 5/1/2035 | |
| RSU | ◇ | ◇ | — | — | |
| Melanie Gloria | RSU | ◇ | ◇ | — | — |
| Option | ◇ | — | ◇ | 11/18/2034 | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | 4/1/2035 | |
| Eric Venker | Option | ◇ | — | ◇ | 7/28/2035 |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.
Director compensation
What each non-employee director was paid.
Fiscal 2026
| Director | Fees earned in cash | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|
Frank M. Torti, M.D Board chair | ◇ | ◇ | ◇ | — | — | — | ◇ |
Jacob Bauer | ◇ | ◇ | ◇ | — | — | — | ◇ |
Robert Susman | ◇ | ◇ | ◇ | — | — | — | ◇ |
George Migausky | ◇ | ◇ | ◇ | — | — | — | ◇ |
Andrew Fromkin | ◇ | ◇ | ◇ | — | — | — | ◇ |
Douglas Hughes | ◇ | ◇ | ◇ | — | — | — | ◇ |
Atul Pande, M.D | ◇ | ◇ | ◇ | — | — | — | ◇ |
Peter Salzmann, M.D and Eric Venker, M.D., Pharm.D served on the board in fiscal 2026 and received no compensation for board service. Executive directors are typically paid through their executive roles, shown above.
Earlier years are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.
Director fee schedule
The standing retainers and premiums the board pays, as published.
| Board cash retainer | ◇ |
| Board equity retainer | ◇ |
| Total board retainer | ◇ |
| Audit committee chair | ◇ |
| Audit committee member | ◇ |
| Compensation committee chair | ◇ |
| Compensation committee member | ◇ |
| Nominating and governance chair | ◇ |
| Nominating and governance member | ◇ |
Equity is delivered as 75% RSU / 25% Option.
Disclosed peer group
The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.
Fiscal 2026
- Apogee Therapeutics APGE
- Arcellx ACLX
- Arrowhead Pharmaceuticals ARWR
- Biohaven BHVN
- BridgeBio Pharma BBIO
- Celldex Therapeutics CLDX
- CRISPR Therapeutics AG CRSP
- Cytokinetics CYTK
- Denali Therapeutics DNLI
- Kymera Therapeutics KYMR
- Madrigal Pharmaceuticals MDGL
- Nuvalent NUVL
- SpringWorks Therapeutics SWTX
- Viridian Therapeutics VRDN
- Xencor XNCR
- Xenon Pharmaceuticals XENE
Say-on-pay history
Shareholder support for the compensation program, by year.
| Year | Meeting | Support | Votes for | Votes against | Abstentions |
|---|---|---|---|---|---|
| 2026 | September 2, 2026 | = | ◇ | ◇ | ◇ |
| 2025 | August 27, 2025 | = | ◇ | ◇ | ◇ |
| 2024 | August 12, 2024 | = | ◇ | ◇ | ◇ |
| 2023 | August 21, 2023 | = | ◇ | ◇ | ◇ |
| 2022 | August 17, 2022 | = | ◇ | ◇ | ◇ |
| 2021 | September 9, 2021 | = | ◇ | ◇ | ◇ |
Chief executive pay ratio
As calculated and reported by the company.
Ratio
◇
Median employee compensation
◇
Chief executive total compensation
◇
What this page does not include
Everything above is a fact Immunovant disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Peer benchmarking
Where Immunovant sits against its disclosed peers — percentile position by role and by pay element, and the ranking behind it. The disclosed peer group is free; comparisons across it are part of the Velarion platform.
Executive Compensation Report — $1,500Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation Report — $1,500Board and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance Report — $1,200Realizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion IntelligenceAdviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Inquire about accessMultiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion IntelligenceCitations
Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
319 figures on this page: 313 cited to the filing that reported them, 6 calculated from figures it prints.
313 cited to the filing
6 calculated from the filing
Documents cited
- 0001764013-26-000106Item 5.07 Submission of Matters to a Vote of Security Holders
- 0001764013-26-000092CEO Pay Ratio · DIRECTOR COMPENSATION · Director Compensation Practice · FY2026 Summary Compensation Table · and 3 more sections
- 0001764013-25-000132
- 0001764013-25-000103Fiscal 2025 Summary Compensation Table · Summary Compensation Table
- 0001764013-24-000150
- 0001764013-23-000097
- 0001764013-22-000108
- 0001764013-21-000098
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “Immunovant executive compensation, FY2024–FY2026.” https://intel.velarion.ai/comp/IMVT (accessed 2026).
Short form: data: Velarion
The Immunovant brief, $1,500
Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
Both reports for $2,400.
8 filings cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about Immunovant and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.
Peers Immunovant discloses
The companies named in IMVT's own disclosed peer group.
Terms on this page
Free to read and cite. Redistribution or bulk use of the dataset requires a data license. Talk to us about the data license.
Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
author = {{Velarion Company Intelligence}},
title = {Velarion database: executive and board compensation data},
year = {2026},
version = {2026Q3},
doi = {10.5281/zenodo.22283854},
publisher = {Zenodo},
url = {https://doi.org/10.5281/zenodo.22283854}
}